Cargando…

Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients

Hyperphosphatemia in chronic kidney disease (CKD) has been associated with elevated cardiovascular morbidity and mortality. Serum phosphate control remains a cornerstone of the clinical management of patients with CKD, in order to both attenuate the progression of secondary hyperparathyroidism or bo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lenglet, Aurélie, Liabeuf, Sophie, Guffroy, Pauline, Fournier, Albert, Brazier, Michel, Massy, Ziad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784056/ https://www.ncbi.nlm.nih.gov/pubmed/24000048 http://dx.doi.org/10.1007/s40268-013-0024-6

Ejemplares similares

Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease
por: Lenglet, Aurelie, et al.
Publicado: (2021)

N-methyl-2-pyridone-5-carboxamide (2PY)—Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin
por: Lenglet, Aurélie, et al.
Publicado: (2016)

Comparison of homocitrulline and carbamylated albumin as biomarkers of carbamylation reactions in hemodialyzed patients
por: Lenglet, Aurelie, et al.
Publicado: (2023)

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis
por: Vasantha, J., et al.
Publicado: (2011)

Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease
por: Desjardins, Lucie, et al.
Publicado: (2013)

From old uraemic toxins to new uraemic toxins: place of ‘omics’
por: Massy, Ziad A, et al.
Publicado: (2018)

Uremic Toxins and Vascular Dysfunction
por: Six, Isabelle, et al.
Publicado: (2020)

Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients
por: Shin, Sooyoung, et al.
Publicado: (2014)

Does P-Cresylglucuronide Have the Same Impact on Mortality as Other Protein-Bound Uremic Toxins?
por: Liabeuf, Sophie, et al.
Publicado: (2013)

Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation
por: Liabeuf, Sophie, et al.
Publicado: (2018)

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?
por: El Chamieh, Carolla, et al.
Publicado: (2022)

Total calcium-sensing receptor expression in circulating monocytes is increased in rheumatoid arthritis patients with severe coronary artery calcification
por: Paccou, Julien, et al.
Publicado: (2014)

The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients
por: de Oliveira, Rodrigo Bueno, et al.
Publicado: (2013)

Does kidney transplantation influence a form of discrimination for antihypertensive drugs prescriptions?
por: Cheddani, Lynda, et al.
Publicado: (2021)

A Dialysis Patient With Hyperphosphatemia, Hyperkalemia, and Azotemia Without an Excessive Intake
por: Fukuoka, Kazuhito, et al.
Publicado: (2017)

Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck?
por: Wish, Jay B.
Publicado: (2023)

Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients
por: Liu, Xianhua, et al.
Publicado: (2018)

Npt2a as a target for treating hyperphosphatemia
por: Thomas, Linto, et al.
Publicado: (2022)

Estimated Glomerular Filtration Rate Is a Poor Predictor of the Concentration of Middle Molecular Weight Uremic Solutes in Chronic Kidney Disease
por: Neirynck, Nathalie, et al.
Publicado: (2012)

Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein
por: Liabeuf, Sophie, et al.
Publicado: (2014)

Erratum: Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein
por: Liabeuf, Sophie, et al.
Publicado: (2015)

Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients
por: Shang, Da, et al.
Publicado: (2017)

Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients
por: Imtiaz, Rameez, et al.
Publicado: (2017)

Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients
por: Mary, Aurélien, et al.
Publicado: (2017)

Protein-Bound Uremic Toxins: New Insight from Clinical Studies
por: Liabeuf, Sophie, et al.
Publicado: (2011)

Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients
por: Shang, Da, et al.
Publicado: (2015)

Difference in Profiles of the Gut-Derived Tryptophan Metabolite Indole Acetic Acid between Transplanted and Non-Transplanted Patients with Chronic Kidney Disease
por: Liabeuf, Sophie, et al.
Publicado: (2020)

Hyperphosphatemia Management in Patients with Chronic Kidney Disease
por: Shaman, Ahmed M., et al.
Publicado: (2016)

Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study
por: Silva, Arnold L., et al.
Publicado: (2023)

Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins
por: Laville, Solène M., et al.
Publicado: (2021)

Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia
por: Vallée, Michel, et al.
Publicado: (2021)

Phosphate intake, hyperphosphatemia, and kidney function
por: Rubio-Aliaga, Isabel, et al.
Publicado: (2022)

Hyperphosphatemia and Cardiovascular Disease
por: Zhou, Chao, et al.
Publicado: (2021)

Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients
por: Streja, Elani, et al.
Publicado: (2013)

Prevalence and factors associated with hyperphosphatemia in continuous ambulatory peritoneal dialysis patients: A cross-sectional study
por: Yin, Xiaojing, et al.
Publicado: (2023)

Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis—A Randomized Clinical Trial
por: Ketteler, Markus, et al.
Publicado: (2020)

Hyperphosphatemia: The hidden killer in chronic kidney disease
por: Askar, Akram M.
Publicado: (2015)

The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
por: Shigematsu, Takashi, et al.
Publicado: (2012)

Corrigendum: Prevalence and factors associated with hyperphosphatemia in continuous ambulatory peritoneal dialysis patients: a cross-sectional study
por: Yin, Xiaojing, et al.
Publicado: (2023)

The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease
por: Liabeuf, Sophie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nfgm6gqkvuocrrs80ikn5qk3l3